RxDoctor Payments Data

Rabih Bazzi, MD

Nephrology · Dearborn, MINPI 1235130691

Payments from drug & device makers

$1,031in general payments, 2019–2025

Across 32 payments — averaging $32.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$199
  • AstraZeneca$175
  • Novo Nordisk$134
  • Boston Scientific$130
  • Boehringer Ingelheim$115
  • Amgen$107
  • plus $170 from 6 others

What the payments were for

  • Food & beverage$98195%
  • Education$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,031 in reported general payments places this provider in the 50th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$357,399
Medicare patients
465
Services billed
2,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol511$475,365
JardianceEmpagliflozin119$132,454
LokelmaSodium Zirconium Cyclosilicate81$58,555
VeltassaPatiromer Calcium Sorbitex45$50,664
Calcitriol1,680$43,883
Cinacalcet Hcl56$31,850
JanuviaSitagliptin Phosphate23$26,399
DapagliflozinDapagliflozin Propanediol27$13,597
MyrbetriqMirabegron16$10,641
Tamsulosin Hcl216$3,623
Clonidine28$2,378
Bumetanide77$1,924
Losartan Potassium228$1,865
Potassium Citrate ErPotassium Citrate49$1,699
Potassium Chloride35$1,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$175$533,920592 claims
Boehringer IngelheimJardiance$115$132,454119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 325 nephrology providers in Michigan.

Other nephrology in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →